AR090806A1 - Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii - Google Patents

Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii

Info

Publication number
AR090806A1
AR090806A1 ARP130101348A ARP130101348A AR090806A1 AR 090806 A1 AR090806 A1 AR 090806A1 AR P130101348 A ARP130101348 A AR P130101348A AR P130101348 A ARP130101348 A AR P130101348A AR 090806 A1 AR090806 A1 AR 090806A1
Authority
AR
Argentina
Prior art keywords
glucosids
pirazol
diabetes
treatment
type
Prior art date
Application number
ARP130101348A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR090806(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR090806A1 publication Critical patent/AR090806A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP130101348A 2012-05-10 2013-04-23 Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii AR090806A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26

Publications (1)

Publication Number Publication Date
AR090806A1 true AR090806A1 (es) 2014-12-10

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101348A AR090806A1 (es) 2012-05-10 2013-04-23 Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii

Country Status (42)

Country Link
US (2) US8697849B2 (OSRAM)
EP (1) EP2850084B1 (OSRAM)
JP (1) JP6148725B2 (OSRAM)
KR (1) KR101685779B1 (OSRAM)
AP (1) AP3593A (OSRAM)
AR (1) AR090806A1 (OSRAM)
AU (1) AU2013259946B2 (OSRAM)
BR (1) BR112014026198B1 (OSRAM)
CA (1) CA2869323C (OSRAM)
CL (1) CL2014002845A1 (OSRAM)
CO (1) CO7141429A2 (OSRAM)
CR (1) CR20140473A (OSRAM)
CY (1) CY1117912T1 (OSRAM)
DK (1) DK2850084T3 (OSRAM)
DO (1) DOP2014000250A (OSRAM)
EA (1) EA024207B1 (OSRAM)
EC (1) ECSP14026088A (OSRAM)
ES (1) ES2588835T3 (OSRAM)
GT (1) GT201400242A (OSRAM)
HR (1) HRP20160804T1 (OSRAM)
HU (1) HUE030414T2 (OSRAM)
IL (1) IL235427A (OSRAM)
IN (1) IN2014DN07996A (OSRAM)
JO (1) JO3136B1 (OSRAM)
LT (1) LT2850084T (OSRAM)
MA (1) MA37501B1 (OSRAM)
ME (1) ME02405B (OSRAM)
MX (1) MX357058B (OSRAM)
MY (1) MY177326A (OSRAM)
NZ (1) NZ700356A (OSRAM)
PE (1) PE20142399A1 (OSRAM)
PH (1) PH12014502492B1 (OSRAM)
PL (1) PL2850084T3 (OSRAM)
PT (1) PT2850084T (OSRAM)
RS (1) RS55107B1 (OSRAM)
SG (1) SG11201407345QA (OSRAM)
SI (1) SI2850084T1 (OSRAM)
TN (1) TN2014000410A1 (OSRAM)
TW (1) TWI579295B (OSRAM)
UA (1) UA113086C2 (OSRAM)
WO (1) WO2013169546A1 (OSRAM)
ZA (1) ZA201407531B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
TWI633113B (zh) 2013-10-17 2018-08-21 美國禮來大藥廠 新穎脲化合物
AR098134A1 (es) 2013-11-01 2016-05-04 Lilly Co Eli Compuestos de urea
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
WO2021045159A1 (ja) * 2019-09-04 2021-03-11 日本たばこ産業株式会社 併用医薬による糖尿病の治療又は予防方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL203124B1 (pl) 1999-08-31 2009-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna je zawierająca i związki pośrednie
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
RU2356906C2 (ru) * 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
EP2076503B1 (en) * 2006-05-19 2013-07-17 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound for the treatment of diabetes
JP5144683B2 (ja) 2007-12-27 2013-02-13 キッセイ薬品工業株式会社 ピラゾール誘導体のモノセバシン酸塩
KR101653853B1 (ko) 2009-02-23 2016-09-02 다이쇼 세이야꾸 가부시끼가이샤 Sglt1 저해제로서의 4-이소프로필페닐 글루시톨 화합물
US20120270819A1 (en) 2009-10-02 2012-10-25 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
CA2869323A1 (en) 2013-11-14
ZA201407531B (en) 2016-05-25
BR112014026198A2 (pt) 2017-06-27
TWI579295B (zh) 2017-04-21
US20140162967A1 (en) 2014-06-12
CN104284894B (zh) 2016-02-17
HRP20160804T1 (hr) 2016-08-12
US9296775B2 (en) 2016-03-29
AU2013259946B2 (en) 2015-09-10
KR20150001798A (ko) 2015-01-06
GT201400242A (es) 2015-08-27
WO2013169546A1 (en) 2013-11-14
MA37501B1 (fr) 2016-11-30
HUE030414T2 (en) 2017-05-29
PE20142399A1 (es) 2015-01-22
LT2850084T (lt) 2016-09-12
AP2014008044A0 (en) 2014-11-30
EA201491852A1 (ru) 2015-02-27
CA2869323C (en) 2016-03-29
AU2013259946A1 (en) 2014-10-16
DK2850084T3 (en) 2016-09-12
EP2850084A1 (en) 2015-03-25
TN2014000410A1 (en) 2015-12-21
SG11201407345QA (en) 2014-12-30
PH12014502492A1 (en) 2015-01-12
EP2850084B1 (en) 2016-06-15
CR20140473A (es) 2014-11-21
PH12014502492B1 (en) 2015-01-12
IL235427A (en) 2016-06-30
JP6148725B2 (ja) 2017-06-14
SI2850084T1 (sl) 2016-07-29
EA024207B1 (ru) 2016-08-31
CL2014002845A1 (es) 2015-01-30
PT2850084T (pt) 2016-08-02
ES2588835T3 (es) 2016-11-07
MX2014013615A (es) 2015-02-12
CY1117912T1 (el) 2017-05-17
MY177326A (en) 2020-09-11
AP3593A (en) 2016-02-15
IN2014DN07996A (OSRAM) 2015-05-01
DOP2014000250A (es) 2014-11-30
JP2015516419A (ja) 2015-06-11
ME02405B (me) 2016-09-20
RS55107B1 (sr) 2016-12-30
US20130303471A1 (en) 2013-11-14
JO3136B1 (ar) 2017-09-20
TW201406773A (zh) 2014-02-16
MX357058B (es) 2018-06-25
ECSP14026088A (es) 2015-09-30
CN104284894A (zh) 2015-01-14
NZ700356A (en) 2016-06-24
BR112014026198B1 (pt) 2021-02-02
PL2850084T3 (pl) 2017-05-31
HK1202542A1 (zh) 2015-10-02
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
US8697849B2 (en) 2014-04-15
CO7141429A2 (es) 2014-12-12
MA37501A1 (fr) 2016-03-31

Similar Documents

Publication Publication Date Title
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR077629A1 (es) Mimetico de smac
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR100006A1 (es) Derivados de tubulisina
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
MX2016013052A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
CU20130020A7 (es) Promotores de apoptosis de n-acilsulfonamidas
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
MX342212B (es) Inhibidores de neprilisina.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
AR095097A1 (es) Compuestos de fenoxietoxi
UY35209A (es) Compuestos tricíclicos
MX2017012926A (es) Inhibidores y sus usos.
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas

Legal Events

Date Code Title Description
FG Grant, registration